

Multimorbidity in adult patients diagnosed with atopic dermatitis

Szymon Mućka,¹ Martyna Miodońska,¹ Magdalena Mróz-Dybowska,¹ Anna Żlik,¹ Alicja Grzanka,¹ Robert Pawłowicz,² Andrzej Bożek¹

¹Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, Katowice;

²Department of Internal Medicine, Pneumology and Allergology, Wrocław Medical University, Poland

Abstract

Atopic dermatitis (AD) may be associated with other diseases that could impact the patient's overall health. The aim of this study was to assess the comorbidities observed in patients diagnosed with AD and psoriasis compared to healthy patients. Patients aged 18 and older were recruited using the medical databases of derma-

tology clinics. Initially, 378 patients were selected *via* an analysis of the International Classification of Diseases - tenth revision (ICD-10) codes. Ultimately, 231 patients with atopic dermatitis were included in the study group based on their fulfillment of the Hanifin and Rajka criteria. The sample comprised 104 women and 127 men with an age range of 18-62. In patients with AD, selected lifestyle diseases such as obesity and atherosclerosis occurred significantly less frequently than in patients without AD, including those with other dermatoses. In addition, allergic asthma and type 2 diabetes occurred significantly more often in AD patients than in those without AD ($p < 0.05$).

Correspondence: Andrzej Bożek, Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia in Katowice, Poland.

E-mail: andrzej.bozek@sum.edu.pl

Tel.: +4832 2713165.

Key words: atopic dermatitis; psoriasis; IgE; comorbidities; cancer.

Contributions: SM, substantial contribution to the conception of the work; RP, analysis of data, validation, data curation, and methodology; MM, validation, data curation, and substantial contributions to the design of the work; MD, validation, data curation, and methodology; AŻ, analysis of data, and validation; AG, data curation, validation; AB, acquisition and interpretation of data, conceptualization, and supervision.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: the study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Medical University of Silesia in Katowice, Poland (KNW-1-131/N/9/K).

Consent for publication: informed consent was obtained from all subjects involved in the study.

Availability of data and materials: the data presented in this study are not publicly available due to ethical restrictions but are available from the corresponding author upon reasonable request.

Received: 7 May 2024.

Accepted: 31 August 2024.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Dermatology Reports 2025; 17:10039

doi:10.4081/dr.2025.10039

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Introduction

Atopic dermatitis (AD) is a chronic, complex, inflammatory skin disease that occurs most frequently in children but also affects adults.¹ AD has been consistently associated with other atopic and allergic conditions, often *via* a progression known as the atopic march.² One of the key problems of modern medicine is the coexistence of many diseases, and identifying their mutual relationships is crucial to the administration of comprehensive patient treatment. This also applies to adult patients diagnosed with AD and other comorbidities.

For example, AD and psoriasis are known to co-occur with cardiovascular disease (CVD), metabolic syndrome, and autoimmune diseases, resulting in an “inflammatory skin march”. Patients with AD are likely at a significantly higher risk of obesity and metabolic disorders, which increase the risk of cardiovascular disease.³ Some studies have shown an association between an increased body mass index (BMI) and AD in children and adults, but this requires further research. An increase in the severity of AD has been associated with an elevated risk of CVD.⁴⁻⁷

Moderate-to-severe AD has been found to coexist with an increased prevalence of hypertension compared to healthy controls. Hypertension, particularly systemic cyclosporine A, has also frequently been reported as an adverse event secondary to AD treatment.^{8,9}

The same also applies to the coexistence of atopic dermatitis and bronchial asthma, whose main cause is an immune imbalance.¹⁰ Researchers have indicated that the risk of asthma is higher if AD is diagnosed earlier or if its clinical course is severe.^{11,12}

In the case of diabetes, such relationships may be different. The incidence of AD has been reported to be lower among patients with diabetes mellitus (DM) compared to their counterparts without DM.¹³ In one study, the risk of type 2 diabetes in the AD group was significantly higher than that in the control group.¹⁴ Eczema in adults is a predictor of cardiovascular risk,¹⁵ and genetically predicted AD is a risk factor for both type 1 and type 2 DM.¹⁵

The aim of this study was to assess the co-occurrence of lifestyle diseases, including cancer, in adult patients diagnosed with AD and compare their incidence with patients with or without other dermatoses.

Materials and Methods

Study design

This research involved a retrospective observational study conducted at a single center. The study carried out a comparative analysis of the multi-morbidity profiles of patients with AD in relation to patients with other dermatoses and a control group to assess the possible distinctiveness of this group. To achieve this, medical databases containing detailed histories of the disease, with test results and treatment documentation, were used.

Study groups and control group

Patients over 18 years of age were recruited using the medical databases of dermatology clinics and the hospital's dermatology ward. Initially, 378 patients were selected *via* an analysis of the International Classification of Diseases - tenth revision (ICD-10) codes L-20, L-20.8, and L-20.9. Ultimately, 231 patients with atopic dermatitis were included in the study group based on their fulfillment of the Hanifin and Rajka criteria. Additionally, patients were only included if a documented dermatological examination had been conducted to confirm the diagnosis of AD; this included the attainment of at least 7 points (at least moderate form of the disease) on the Eczema Area and Severity Index (EASI) scale, an increased total IgE concentration in blood serum, at least one positive allergen-specific IgE for an inhalant or food allergen in blood serum, and at least 12 months of documented treatment. Finally, 104 women and 127 men with an age range of 18-62 were included (Table 1).

Due to the hypothesis that the comorbidity profile of patients with AD may differ from patients with other non-allergic dermatoses, the multimorbidity observed in the group of patients with AD was compared with the group of patients without an AD diagnosis (without ICD L-20, L-20.8, and L-20.9; without clinical features of the disease; without dedicated treatment for AD; and with medical documentation excluding AD. The control group included patients with non-allergic skin diseases (eczema and allergic urticaria were excluded), with a low total IgE value and negative allergen-specific and post-acute IgE values. This group comprised 351 patients with an age range of 18-72 and without skin diseases (n=291).

A group of patients diagnosed with AD and a group of patients with other dermatoses were compared with patients without skin disease with regard to comorbidities; the patients in this group were randomly selected from the database of family doctors from the same area and with the same gender and age restrictions. In this group, dermatological diagnoses were excluded based on the ICD-10 code, possible treatment documents, and an analysis of their medical documentation.

In the assessment of comorbidities, the possible occurrence of only chronic, well-documented diseases was evaluated: cardiovascular diseases, asthma, diabetes, chronic obstructive pulmonary disease (COPD), osteoporosis, cancer, hyperlipidemia, hyperuricemia, and other diseases. For the final analysis, these diseases were only diagnosed if they were present in at least 5% of the respondents.

In particular, all past cardiological medical interventions were analyzed based on the database of the National Health Fund, verified with regard to the correct diagnosis, and categorized, as shown in Table 2.

A cluster analysis was performed to identify the different clusters (models) of AD, either associated (ADM) or not associated (ADNM) with atopic dermatitis. The k-means method was used. In the cluster analysis, the following parameters were taken into consideration: sex, BMI, smoking, documented diagnosis of ischemic heart disease, arterial hypertension, DM type 2, COPD, asthma, cancer, atherosclerosis, and osteoporosis. The analysis also used documentation from hospital outpatient clinics and family doctors, in addition to ICD-10 codes, to determine the remaining diseases from the presented list using the database of the National Health Fund.

All patients gave informed consent to participate in the study and consented to sharing all data. Consent was obtained from the Bioethics Committee at the Medical University of Silesia in Katowice (KNW/0022KB1/139/09).

Results

Occurrence of lifestyle diseases

In patients with AD, selected chronic diseases such as obesity

Table 1. Characteristics of the study groups.

Variable	AD (n=231)	Other dermatoses* (n=351)	Controls (n=291)
Mean age (range) in years	38.4 (18-62)	41.2 (18-71)	35.1 (18-66)
Women	45.2% (104) [†]	67% (235)	65.2% (190)
BMI (±SD)	26.5±2.6	24.7±3.6	25.9±2.1
Smokers	19.9% (46)	20.1% (70.6)	22.6% (66)
Urban area	78.6% (181) [^]	52.1% (182)	54.3% (158)
Mean duration of the dermatoses in years	24.1 [§]	7.1	-
Hospitalizations per year	0.45	0.55	0.47
Higher education	34.1% (79) [#]	20.1% (71)	22.9% (66)
Same dermatosis in the family	16.2% (37)	13.9% (49)	-
Immunosuppressive therapy	33.1% (76)	29.8% (105)	-
Biological therapy	9.2% (21)	15.7% (55) [°]	-

AD, atopic dermatitis; *chronic urticaria, psoriasis, cutaneous vasculitis, lupus, and scleroderma; parametric variables were compared using the ANOVA test, and non-parametric variables were compared using the Kruskal-Wallis ANOVA test (significance at $p < 0.05$); [†]male dominance in the AD group compared to the other groups ($p < 0.05$); BMI, body mass index; SD, standard deviation; [^]AD patients more often live in urban areas compared to the other groups ($p < 0.05$); [§]the duration of AD is significantly longer than that of other analyzed dermatoses ($p < 0.05$); [#]AD patients have a higher education level than those in the other groups ($p < 0.05$); [°]patients with other dermatoses are more often treated with biological therapy (especially those with diagnosed psoriasis, $p < 0.05$).

and atherosclerosis occurred significantly less frequently than in patients without AD, including those with other dermatoses. Allergic asthma and type 2 diabetes, as well as the use of oral glucocorticosteroid therapy, were more common in AD patients than in others. Detailed data are presented in Table 2.

Other chronic diseases

No significant differences were observed between groups regarding the remaining chronic diseases to be analyzed (Figure 1). In all analyzed groups, the most common disease was hyperlipidemia, followed by depression.

Profiles of cancer incidence

There were no significant statistical differences in the distribution or incidence of the most common cancers in the individual study groups. All groups were dominated by lung, colon, prostate, and breast cancer (Figure 2).

Cluster analysis of the studied groups

Five cluster models were created (Table 3). Patients with AD were highly concentrated in clusters 1 and 5 (Figure 3). In these




Figure 2. Percentage distribution of types of cancer in the studied groups. 100% is the sum of all diagnosed cancers in the study group; AD, atopic dermatitis; other dermatoses: chronic urticaria, psoriasis, cutaneous vasculitis, lupus, and scleroderma. There were no significant differences between the cancer profiles of the groups (Kruskal-Wallis ANOVA test $p>0.05$).




Figure 1. Percentage of selected chronic diseases in the study groups. AD, atopic dermatitis; other dermatoses: chronic urticaria, psoriasis, cutaneous vasculitis, lupus, scleroderma. There were no significant differences between the study groups for each disease analyzed using the Kruskal-Wallis ANOVA test ($p>0.05$).




Figure 3. Proportion of patients with AD or without for each cluster (1-5). Percentage dominance of AD patients in clusters 1 and 5 ($p<0.05$) compared to the others.

Table 2. The occurrence of the most common chronic diseases in the studied groups.

Variable	AD (n=231)	Other dermatoses* (n=351)	Controls (n=291)
Ischemic heart disease	8 (3.5%)	15 (4.3%)	11 (3.8%)
Arterial hypertension	76 (32.9%)	127 (36.2%)	102 (35.1%)
Type 2 diabetes	11 (4.8%) [†]	8 (2.3%)	10 (3.4%)
COPD	29 (12.5%)	48 (13.6%)	39 (13.4%)
Asthma	51 (22%) [^]	24 (6.8%)	19 (6.5%)
Cancer	38 (16.5%)	61 (17.3%)	82 (28.2%)
Atherosclerosis	8 (3.5%) [§]	27 (7.8%)	21 (7.2%)
Osteoporosis	12 (5.2%)	31 (8.8%) [#]	19 (6.5%)
Obesity (BMI≥30)	31 (13.4%) [°]	68 (19.3%) [°]	69 (23.7%) [°]
Oral GCS	113 (48.9%) ^{**}	101 (28.8%) ^{**}	32 (10.9%) ^{**}

AD, atopic dermatitis; *chronic urticaria, psoriasis, cutaneous vasculitis, lupus, scleroderma; all non-parametric variables were compared using the Kruskal-Wallis ANOVA test (significance at $p<0.05$); COPD, chronic obstructive pulmonary disease; BMI, body mass index; oral GCS, oral glucocorticosteroid therapy (minimum 5-day treatment course); [†]type 2 diabetes moderately predominates in the AD group compared to the other groups ($p<0.05$); [^]AD patients more often have asthma compared to the other groups ($p<0.05$); [§]AD patients are less likely to be diagnosed with atherosclerosis than those in the other groups ($p<0.05$); [#]osteoporosis occurs more often in patients with other dermatoses ($p<0.05$); [°]all studied groups differed significantly in the prevalence of obesity: lowest prevalence in the AD group, highest prevalence in the control group ($p<0.05$); ^{**}all studied groups differed significantly in the prevalence of using oral glucocorticosteroids: highest prevalence in AD group, lowest prevalence in control group ($p<0.05$).

two clusters, a generally lower incidence of other diseases was observed; in particular, a lower incidence of cancer and type 2 diabetes was noted. However, asthma and depression were more common in these two clusters.

The characteristics of individual clusters were as follows:

- Cluster 1 was characterized by a high prevalence of AD, asthma, Hashimoto's thyroiditis, depression, and type 2 diabetes. Atherosclerosis was rarely observed in this group.
- Cluster 2 showed a frequent occurrence of cancers and hyperlipidemia, while dermatoses were infrequently reported.
- Cluster 3 was marked by a high prevalence of cancers, osteoporosis, rheumatoid diseases, and dermatoses.
- Cluster 4 demonstrated frequent comorbidities, including cancers, obesity, and hyperlipidemia. Celiac disease was rarely present in this cluster.
- Cluster 5 was predominantly associated with AD, asthma, and type 2 diabetes.

Discussion

The assessment of comorbidities in relation to AD is a complex process, and the presented observations must be related to the specificity of the Polish population under study. Because lifestyle, eating habits, environmental factors, and medical care have a significant impact on the results, these factors should be treated individually. A good example is the assessment of the prevalence of diabetes in a given population and its relationship with other diseases. The obtained results indicate that type 2 diabetes occurs slightly more often in patients with AD than in other subjects. This may be explained by the fact that oral steroids are used more frequently in these patients. However, the opinions of authors regarding this subject diverge significantly and depend largely on the type of population studied. Andresen *et al.*¹⁶ found a higher prevalence of type 2 diabetes in patients with AD than in the general

population in the US. A possible explanation for this putative relationship is the shared genetic risk *loci* between AD and type 2 diabetes, which results in the diabetogenic effects of chronic systemic low-grade inflammation in moderate-to-severe AD.¹⁶ However, the small representative group used in the current study does not allow us to assess any possible correlation between the occurrence of type 2 diabetes and the severity of AD. A contrary opinion is presented by Gonzalez-Urbe *et al.*,¹⁷ who concluded that the risk of diabetes is linked primarily to obesity and tobacco use and did not consider AD to represent an independent risk factor. In their meta-analysis, Thyssen *et al.*¹⁸ also confirmed that there is no association between AD and unspecified but suspected type 2 diabetes. The same authors also pointed out that AD, in some populations, is associated with an increased prevalence of cardiovascular risk factors, such as obesity and smoking. However, it is unlikely that AD represents an independent and clinically relevant risk factor for cardiometabolic disease.¹⁸⁻²⁰ The incidence of obesity varies depending on the population studied, *e.g.*, European vs. American, which makes it exceedingly difficult to unify such relationships.¹⁸ The most interesting finding of our study may be the lower prevalence of obesity and the lower risk of developing atherosclerosis observed in patients with AD. However, when comparing these data with the observations of other authors, it seems that obesity, atherosclerosis, and risk of cardiovascular disease may be independent of the occurrence of AD; in the case of our patients, this observation does not constitute evidence of the protective effect of AD but is rather a feature of this specific population.^{18,19} It is also worth noting that despite the smaller group of patients with AD and cardiovascular disease included in this study, a large group of patients had the features of hyperlipidemia in the analyzed additional tests, as shown in Figure 1. This apparent discrepancy only proves the risk of cardiovascular and other diseases for all examined patients. However, some authors have confirmed that there is a higher incidence of obesity in patients with severe AD, which may result from the use of glucocorticosteroids or comorbidities in general.^{17,21,22} Analyzing this finding in detail

Table 3. Cluster analysis of the entire study population (n=813).

n=813	Cluster 1 (n=178)	Cluster 2 (n=243)	Cluster 3 (n=115)	Cluster 4 (n=159)	Cluster 5 (n=118)
Comorbidities	13.8	18.9	31.2	49.4	8.9
Ischemic heart disease	11.2	10.2	13.8	7.8	4.3
Arterial hypertension	18.5	16.3	11.3	17.4	10.9
Type 2 diabetes	10.8	3.5	2.1	5.5	11.8
COPD	3.8	11.2	2.8	2.2	4.5
Asthma	11.4	3.2	1.9	1.2	16.5
Cancer	7.8	13.8	15.9	11.2	5.3
Atherosclerosis	3.2	8.11	9.3	5.1	4.9
Osteoporosis	5.5	4.7	9.9	5.7	5.2
Obesity (BMI≥30)	9.1	10.9	10.1	19.3	12.8
Gout	8.1	7.4	5.9	10.2	11.2
Rheumatoid	5.8	1.9	11.5	4.3	7.3
Hashimoto	14.5	9.8	11.2	10.4	10.3
Hyperlipidemia	25.9	28.1	22.7	28.2	19.1
Celiac	1.8	2.4	3.1	0.9	4.5
Depression	12.3	7.8	4.1	6.5	7.4
Liver failure	2.1	1.8	5.3	4.9	6.1
Renal failure	0.9	1.1	3.2	0.5	0.9
No dermatoses	12.7	30.1	9.5	24.6	23.1

The proportion of variables in each cluster is shown as a percentage; COPD, chronic obstructive pulmonary disease; BMI, body mass index.

would require international prospective comparative studies.

A more expected result is the higher prevalence of asthma observed in the AD group. This is evidence of the presence of atopic comorbidities, which have been described and confirmed in many studies. Asthma was confirmed in 22% of adult patients with AD. This prevalence is comparable to that observed in the Ravenborg study, which confirmed the presence of asthma in 25.7% of AD patients, with the risk of this disease possessing an odds ratio of 3.3.¹² Epidemiological studies of adults in the Polish population (ECAP) have confirmed a similar relationship.²³ These studies have examined various atopic comorbid disease trajectories and found that it is probable that several pathways and mechanisms are at play. Some of these may be shared across all atopic/T helper (TH) 2-dominant diseases, while others could be specific to diseases.²⁴ Some authors have suggested that early childhood AD fosters the emergence of food allergies and respiratory allergies. This is believed to be a result of systemic sensitization, which is a consequence of compromised skin barrier function. This hypothesis, which attributes the primary cause of atopic diseases to a deficiency in epithelial barrier integrity, has been endorsed by several studies.^{25,26}

The results of this study indicate that, in general, the frequency profile of many non-atopic diseases does not differ significantly among different patients. However, the data in the literature regarding this topic are ambiguous.^{3,4,26} This may once again prove that AD or other dermatoses do not constitute a separate risk factor for these diseases. For example, some authors have emphasized that the incidence of cardiovascular diseases is higher in patients with dermatoses than in the general population. However, this applies to all vascular diseases, including peripheral circulation disorders and strokes.²⁷⁻²⁹ Some authors have observed an increase in the presence of osteoporosis in patients with atopic dermatitis, but the present study did not confirm this.^{27,28} Such authors have attempted to explain this finding by referring to the lower quantity of systemic steroids used in treatment. In addition, unlike those cited, the predominant inclusion of men in this type of study may result in a lower incidence of osteoporosis (a minor component of menopausal osteoporosis).^{27,28}

The occurrence of cancer also requires discussion. A similar profile of occurrence was recorded for all groups, regardless of the statistical method used, including cluster analysis. This may be in opposition to previous hypotheses suggesting that atopy protects, to some extent, against cancer.²⁹ On the other hand, when considering the remaining groups, it also appears that the presence of other dermatoses is not an independent factor that affects the induction of cancer. However, this conjecture must be met with caution, as individual types of dermatoses other than AD have not been analyzed separately. In this study, the prevalence of cancer did not differ significantly from that observed by other authors.³⁰ On the other hand, the cluster analysis showed that models 1 and 5, comprising predominantly AD patients, had a lower incidence of comorbidities, especially cancers. It is worth emphasizing that some studies have confirmed that skin keratinocyte cancer occurs more frequently in patients with AD, but this was not confirmed in the present study.³¹

The data obtained regarding the confirmation of depression in patients with AD seem to be lacking, which may be due to a lack of prospective assessments. A higher risk of depression was only visible in the cluster analysis (cluster 1). Most authors have indicated that this group is most likely to be diagnosed with depression, but emphasize that it is often underdiagnosed.^{32,33}

The limitations of this study include the relatively small study groups used, its retrospective nature, and the limited number of assessed disease entities, resulting from the focus on the ICD-10

code. On the other hand, such a restriction made the obtained data seem reliable. Analyzing age subgroups could have improved the reliability of these data, but the underrepresentation of the oldest patient group prevented this.

Conclusions

In some AD patients, comorbidities associated with allergic asthma and type 2 diabetes are more prevalent. However, the prevalence of other chronic diseases, such as osteoporosis, hyperlipidemia, and allergic rhinitis, has also been noted. For this reason, patients with AD particularly require comprehensive medical care.

References

1. Spergel JM. From atopic dermatitis to asthma: the atopic march. *Ann Allergy Asthma Immunol* 2010;105:99-106; quiz 107-9, 117.
2. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. *Allergy* 2014;69:17-27.
3. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. *Exp Dermatol* 2018;27:409-17.
4. Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and meta-analysis. *J Am Acad Dermatol* 2015;72:606-16.e4.
5. Silverberg JI, Becker L, Kwasny M, et al. Central obesity and high blood pressure in pediatric patients with atopic dermatitis. *JAMA Dermatol* 2015;151:144-52.
6. Silverberg JI, Silverberg NB, Lee-Wong M. Association between atopic dermatitis and obesity in adulthood. *Br J Dermatol* 2012;166:498-504.
7. Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. *J Allergy Clin Immunol* 2019;143:1821-9.
8. Yousaf M, Ayasse M, Ahmed A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis. *Br J Dermatol* 2022;186:227-35.
9. Amber T, Tabassum S. Cyclosporin in dermatology: a practical compendium. *Dermatol Ther* 2020;33:e13934.
10. Yaneva M, Darlenski R. The link between atopic dermatitis and asthma- immunological imbalance and beyond. *Asthma Res Pract* 2021;7:16.
11. Li H, Dai T, Liu C, et al. Phenotypes of atopic dermatitis and the risk for subsequent asthma: a systematic review and meta-analysis. *J Am Acad Dermatol* 2022;86:365-72.
12. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. *J Am Acad Dermatol* 2021;84:471-8.
13. Mirghani HO, Alhazmi K, Alghamdi S, et al. The cross-talk between atopic dermatitis and diabetes mellitus: a meta-analysis. *Cureus* 2021;13:e13750.
14. Lee SW, Park J, Kim H, et al. Risk of type 2 diabetes mellitus in adult patients with atopic dermatitis. *Diabetes Res Clin Pract* 2023;204:110883.
15. Lu F, Wu B, Wang Y. Mendelian randomization indicates that atopic dermatitis contributes to the occurrence of diabetes. *BMC Med Genomics* 2023;16:132.

16. Andersen YMF, Egeberg A, Gislason GH, et al. Adult atopic dermatitis and the risk of type 2 diabetes. *J Allergy Clin Immunol* 2017;139:1057-9.
17. Gonzalez-Uribe V, Cruz HVDL, Gomez-Nuñez A, et al. Comorbidities & burden of disease in atopic dermatitis. *Asian Pac J Allergy Immunol* 2023;41:97-105.
18. Thyssen JP, Halling-Overgaard AS, Andersen YMF, et al. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol* 2018;178:1272-9.
19. Carrascosa JM, Morillas-Lahuerta V. Comorbidities in atopic dermatitis: an update and review of controversies. *Actas Dermosifiliogr (Engl Ed)* 2020;111:481-6.
20. Thyssen JP, Egeberg A. Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations. *Br J Dermatol* 2018;179:1014-5.
21. Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis-what does the evidence say? *J Allergy Clin Immunol* 2023;151:1155-62.
22. Egeberg A, Andersen YM, Gislason GH, et al. Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. *Allergy* 2017;72:783-91.
23. Sybilski AJ, Raciborski F, Lipiec A, et al. Epidemiology of atopic dermatitis in Poland according to the epidemiology of allergic disorders in Poland (ECAP) study. *J Dermatol* 2015;42:140-7.
24. Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. *J Allergy Clin Immunol* 2019;143:46-55.
25. Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: an overview. *Clin Exp Allergy* 2018;48:919-34.
26. Hogan MB, Peele K, Wilson NW. Skin barrier function and its importance at the start of the atopic march. *J Allergy (Cairo)* 2012;2012:901940.
27. Wu CY, Lu YY, Lu CC, et al. Osteoporosis in adult patients with atopic dermatitis: a nationwide population-based study. *PLoS One* 2017;12:e0171667.
28. Shaheen MS, Silverberg JI. Atopic dermatitis is associated with osteoporosis and osteopenia in older adults. *J Am Acad Dermatol* 2019;80:550-1.
29. Skaaby T, Husemoen LLN, Roswall N, et al. Atopy and development of cancer: a population-based prospective study. *J Allergy Clin Immunol Pract* 2014;2:779-85.
30. Halling-Overgaard AS, Ravnborg N, Silverberg JI, et al. Atopic dermatitis and cancer in solid organs: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2019;33:e81-2.
31. Das P, Mounika P, Yellurkar ML, et al. Keratinocytes: an enigmatic factor in atopic dermatitis. *Cells* 2022;11:1683.
32. Rønnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. *J Am Acad Dermatol* 2018;79:448-56.e30.
33. Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. *J Am Acad Dermatol* 2019;80:402-10.